from Wiktionary, Creative Commons Attribution/Share-Alike License
- n. Any substance that elicits a immune response; an antigen
from the GNU version of the Collaborative International Dictionary of English
- n. any substance that produces immunity when introduced into the body.
from WordNet 3.0 Copyright 2006 by Princeton University. All rights reserved.
- n. any substance or organism that provokes an immune response (produces immunity) when introduced into the body
Sorry, no etymologies found.
In contrast, Provenge is a vaccine derived from an external immunogen specific to prostate cancer.
Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor.
Any suitable source of IL-10 can be used as the immunogen for the generation of the non-human antibody of the compositions and methods disclosed herein.
Bartlett JA, Wasserman SS, Hicks CB, Dodge RT, Weinhold KJ, et al. (1998) Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen.
R, Moody MA, Haynes BF, Spicer LD (1996) Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF.
RJ, Ferre F, Daigle AE, Jensen FC, Moss RB, et al. (1994) Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells.
RJ, Daigle AE, Giermakowska W, Moss RB, Jensen F, et al. (1995) Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of
JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, et al. (2001) A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.
Results of the first Phase 1 clinical trial of RiVax (TM) indicated that the immunogen was safe and induced antibodies anticipated to protect humans from ricin exposure.
Immunovo combines the most desirable features of synthetic immunogen development with the recent insights into mechanisms driving tumor growth and metastasis, to create highly specific and powerful in vivo therapeutic immune responses.